KURA - NASDAQ

Kura Oncology, Inc.

KURA·NASDAQ

$8.65

-3.5%

HealthcareBiotechnology

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$768.34M

EPS-3.1800

P/E Ratio-2.72

Earnings Date07/30/2026

738.36M

Assets

-3%

3Y+62.0%

5Y+14.0%

10Y+958.0%

564.23M

Total Liabilities

63%

3Y+1466.0%

5Y+1454.0%

10Y+4259.0%

174.13M

Total Equity

-58%

3Y-59.0%

5Y-71.0%

10Y+206.0%

Kura Oncology, Inc. Funding & Solvency Profile

KURA · NASDAQ

Current Assets

Cash & Cash Equivalents149.10M

Net Receivables12.60M

Inventory413.00K

Other Current Assets28.41M

Total Current Assets709 M

Non-Current Assets

Property, Plant & Equipment15.16M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets14.54M

Total Non-Current Assets30 M

Total Assets

738.36M

Financial Health Analysis

Current Ratio

6.06x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

3.24x

High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.

Working Capital

592 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

96% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.

Kura Oncology, Inc. Balance Sheet

KURA • NASDAQ

Kura Oncology, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	149.1M	224.5M	37.3M	51.8M	90.7M	325.5M	26.1M	16.1M	11.4M	9.7M	15.4M	1.1M	6.6K	4.8K	4.2K	26.9K	11.1K	7.5K
Short-Term Investments	518.1M	502.9M	386.6M	386.2M	427.3M	307.8M	210.8M	162.9M	81.7M	58.1M	70.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	667.2M	727.4M	424M	438M	518M	633.3M	236.9M	179M	93.1M	67.8M	85.7M	1.1M	6.6K	4.8K	4.2K	26.9K	11.1K	7.5K
Net Receivables	12.6M	0.0	0.0	0.0	0.0	0.0	30K	224K	216K	295K	430K	30K	0.0	0.0	0.0	0.0	0.0	0.0
Accounts Receivables	8.8M	0.0	0.0	0.0	0.0	0.0	30K	224K	216K	295K	430K	30K	0.0	0.0	0.0	0.0	0.0	0.0
Other Receivables	3.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	413K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	0.0	4.3M	4M	2.7M	2M	1.3M	725K	693K	42K	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Assets	28.4M	17.4M	8.5M	8.4M	0.0	0.0	-30K	2M	1.3M	725K	0.0	0.0	0.0	3.5K	2.5K	0.0	0.0	0.0
Total Current Assets	708.7M	744.8M	432.5M	446.4M	522.3M	637.3M	239.6M	181.2M	94.6M	68.8M	86.9M	1.2M	6.6K	8.3K	6.7K	26.9K	11.1K	7.5K
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	15.2M	7.5M	8.9M	6.4M	8.2M	8.4M	278K	0.0	10K	40K	71K	27K	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	14.5M	7.8M	7.6M	3.5M	3.5M	1.6M	2.1M	1.2M	1.2M	971K	319K	155K	2.5K	0.0	0.0	0.0	0.0	0.0
Total Non-Current Assets	29.7M	15.3M	16.5M	9.9M	11.8M	9.9M	2.4M	1.2M	1.2M	1M	390K	182K	2.5K	0.0	0.0	0.0	0.0	0.0
Other Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5K	1.9K	0.0
Total Assets	738.4M	760.2M	448.9M	456.3M	534.1M	647.2M	242M	182.4M	95.9M	69.8M	87.3M	1.4M	9.1K	8.3K	6.7K	29.4K	13K	7.5K
LIABILITIES
CURRENT LIABILITIES
Total Payables	5.3M	3.5M	2.3M	1.5M	3.2M	2.8M	3.5M	4.1M	1.2M	638K	928K	226K	350.0	1.9K	2.9K	0.0	0.0	0.0
Accounts Payable	5M	1.5M	2.3M	1.5M	3.2M	2.8M	3.5M	3.9M	1.2M	638K	928K	226K	350.0	1.9K	2.9K	0.0	0.0	0.0
Other Payables	239K	2.1M	0.0	0.0	0.0	0.0	0.0	370K	0.0	0.0	0.0	0.0	-350.0	-1.9K	-2.9K	0.0	0.0	0.0
Accrued Expenses	0.0	28.9M	18.3M	9.9M	9M	11.2M	7.8M	9.7M	7.3M	4.8M	4.1M	754K	0.0	0.0	0.0	0.0	0.0	0.0
Short Term Debt	1.3M	2.6M	0.0	0.0	0.0	3M	250K	0.0	1.5M	0.0	0.0	2M	110K	85K	60K	60K	25K	0.0
Capital Lease Obligations (Current)	0.0	1.9M	1.5M	2.3M	2.3M	2.1M	252K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	2.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	24.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	110.4M	17.5M	13.2M	10.3M	7.9M	7M	3.7M	-185K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Current Liabilities	117M	78.7M	35.3M	24.1M	22.5M	26M	15.6M	13.6M	10M	5.5M	5.1M	3M	110.4K	103.6K	74.8K	60K	25K	0.0
NON-CURRENT LIABILITIES
Long Term Debt	9.7M	6.9M	9.3M	9.2M	0.0	4.3M	7.3M	7.5M	5.6M	7.3M	0.0	493K	110K	85K	60K	0.0	0.0	0.0
Deferred Revenue (Non-Current)	424.9M	253.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	3.2M	1.8M	705K	265K	375K	395K	377K	279K	388K	170K	101K	1.3M	-87.3K	-68.2K	-48.2K	10.4K	6.6K	0.0
Total Non-Current Liabilities	447.3M	267.8M	16.4M	12M	5M	10.3M	7.6M	7.8M	6M	7.5M	101K	1.8M	110K	85K	60K	10.4K	6.6K	0.0
Other Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-87.3K	-85K	-60K	0.0	0.0	0.0
Capital Lease Obligations	9.5M	7.1M	7.9M	4.9M	6.9M	7.7M	252K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	564.2M	346.5M	51.7M	36M	27.4M	36.3M	23.2M	21.4M	16M	12.9M	5.2M	4.8M	133K	103.6K	74.8K	70.4K	31.6K	0.0
SHAREHOLDERS' EQUITY
Common Stock	9K	8K	7K	7K	7K	7K	5K	4K	3K	2K	2K	50K	500.0	500.0	500.0	500.0	500.0	500.0
Additional Paid-In Capital	1.3B	1.3B	1.1B	997.1M	941.4M	913.4M	431.3M	310.8M	169.2M	110.7M	108.5M	237K	0.0	0.0	0.0	0.0	0.0	0.0
Retained Earnings	-1.2B	-895.4M	-721.4M	-568.8M	-433M	-302.5M	-212.9M	-149.7M	-89.3M	-53.9M	-26.3M	-3.7M	-174K	-145.3K	-118K	-91K	-68.6K	-48.6K
Accumulated Other Comprehensive Income/Loss	1M	764K	-1.3M	-8M	-1.8M	46K	331K	-131K	-49K	-18K	-87K	-1K	0.0	0.0	0.0	0.0	0.0	0.0
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	539.0	49.5K	49.5K	49.5K	49.5K	49.5K	49.5K
Total Stockholders' Equity	174.1M	413.6M	397.3M	420.3M	506.6M	610.9M	218.8M	161M	79.9M	56.9M	82.1M	-3.4M	-124K	-95.3K	-68K	-41K	-18.6K	1.4K
Total Equity	174.1M	413.6M	397.3M	420.3M	506.6M	610.9M	218.8M	161M	79.9M	56.9M	82.1M	-3.4M	-124K	-95.3K	-68K	-41K	-18.6K	1.4K
SUMMARY
Total Liabilities & Equity	738.4M	760.2M	448.9M	456.3M	534.1M	647.2M	242M	182.4M	95.9M	69.8M	87.3M	1.4M	9.1K	8.3K	6.7K	29.4K	13K	7.5K
Total Investments	518.1M	502.9M	386.6M	386.2M	427.3M	307.8M	210.8M	162.9M	81.7M	58.1M	70.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Debt	20.5M	16.6M	17.2M	14M	6.9M	15M	7.8M	7.5M	7.1M	7.3M	0.0	2.5M	220K	170K	120K	60K	25K	0.0
Net Debt	-128.6M	-207.9M	-20.1M	-37.8M	-83.8M	-310.5M	-18.4M	-8.6M	-4.3M	-2.4M	-15.4M	1.4M	213.4K	165.2K	115.8K	33.1K	13.9K	-7.5K
Shares Outstanding	87,017,500	87,017,500	87,017,500	87,017,500	87,017,500	87,017,500	87,017,500	87,017,500	87,017,500	87,017,500	87,017,500	87,017,500	87,017,500	87,017,500	87,017,500	87,017,500	87,017,500	87,017,500

SEC Filings

KURA - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 12, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 12, 2026	May 12, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 10, 2026	June 04, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 05, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 05, 2026	March 05, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 29, 2026	January 28, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 11, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 02, 2025	December 02, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 13, 2025	November 13, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 04, 2025	November 04, 2025	2025	View Filing

Showing 1 to 10 of 241 filings

Related Guides

Blog Categories

Continue your KURA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.